<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00333567</url>
  </required_header>
  <id_info>
    <org_study_id>CCOX189A2427</org_study_id>
    <nct_id>NCT00333567</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy of a Single Dose of Lumiracoxib 400 mg Given Pre-Emptively Versus Post-Operatively, in Reducing Pain Associated With Ambulatory Arthroscopic Knee Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to investigate the efficacy and safety of a single daily dose of 400
      mg lumiracoxib given pre-emptively versus post-operatively in terms of efficacy in reducing
      pain associated with ambulatory arthroscopic knee surgery
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity (PI) in the target knee after movement at the 2 h time-point</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>PI at 1, 2, 3, 4 and 24 h time-points while at rest</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PI at 1, 3, 4 and 24 h time-points after movement</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first rescue medication intake</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global evaluation of response to study medication</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability profile</measure>
  </secondary_outcome>
  <enrollment>110</enrollment>
  <condition>Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumiracoxib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who need scheduled minor ambulatory arthroscopic knee surgery.

        Exclusion Criteria:

          -  Patients with any surgical or medical conditions which could place the patient at
             higher risk from his/her participation in the study, or are likely to prevent the
             patient from complying with the requirements of the study or completing the trial
             period.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharma AG</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Nuernberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2006</study_first_submitted>
  <study_first_submitted_qc>June 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2006</study_first_posted>
  <last_update_submitted>December 12, 2007</last_update_submitted>
  <last_update_submitted_qc>December 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2007</last_update_posted>
  <keyword>arthroscopic knee surgery</keyword>
  <keyword>cyclooxygenase-2 inhibitors</keyword>
  <keyword>lumiracoxib</keyword>
  <keyword>COX189</keyword>
  <keyword>Ambulatory arthroscopic knee surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumiracoxib</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

